Cost-effectiveness of 3 months of weekly rifapentine and isoniazid compared with other standard treatment regimens for latent tuberculosis infection: a decision analysis study

Simple item page
dc.contributor.authorDoan, Tan N
dc.contributor.authorFox, Greg
dc.contributor.authorMeehan, Michael
dc.contributor.authorNick, Scott
dc.contributor.authorRagonnet, Romain
dc.contributor.authorViney, Kerri
dc.contributor.authorTrauer, James
dc.contributor.authorMcBryde, Emma
dc.date.accessioned2019-10-02T00:57:19Z
dc.date.issued2019
dc.date.updated2019-04-21T08:25:05Z
dc.description.abstractLatent tuberculosis infection (LTBI) is a critical driver of the global burden of active TB, and therefore LTBI treatment is key for TB elimination. Treatment regimens for LTBI include self-administered daily isoniazid for 6 (6H) or 9 (9H) months, self-administered daily rifampicin plus isoniazid for 3 months (3RH), self-administered daily rifampicin for 4 months (4R) and weekly rifapentine plus isoniazid for 3 months self-administered (3HP-SAT) or administered by a healthcare worker as directly observed therapy (3HP-DOT). Data on the relative cost-effectiveness of these regimens are needed to assist policymakers and clinicians in selecting an LTBI regimen.en_AU
dc.format.mimetypeapplication/pdfen_AU
dc.identifier.issn0305-7453en_AU
dc.identifier.urihttp://hdl.handle.net/1885/172083
dc.language.isoen_AUen_AU
dc.publisherOxford University Pressen_AU
dc.relationhttp://purl.org/au-research/grants/nhmrc/1148372en_AU
dc.rights© The Author(s) 2018. Published by Oxford University Press on behalf of the British Society for Antimicrobial Chemotherapyen_AU
dc.sourceJournal of Antimicrobial Chemotherapyen_AU
dc.titleCost-effectiveness of 3 months of weekly rifapentine and isoniazid compared with other standard treatment regimens for latent tuberculosis infection: a decision analysis studyen_AU
dc.typeJournal articleen_AU
local.bibliographicCitation.issue1en_AU
local.bibliographicCitation.lastpage227en_AU
local.bibliographicCitation.startpage218en_AU
local.contributor.affiliationDoan, Tan N, University of Melbourneen_AU
local.contributor.affiliationFox, Greg, Univeristy of Sydneyen_AU
local.contributor.affiliationMeehan , Michael , Australian Institute of Tropical Health and Medicineen_AU
local.contributor.affiliationNick , Scott , The Burnet Instituteen_AU
local.contributor.affiliationRagonnet , Romain , Department of Medicine at the Royal Melbourne Hospitalen_AU
local.contributor.affiliationViney, Kerri, College of Health and Medicine, ANUen_AU
local.contributor.affiliationTrauer , James , School of Public Health and Preventive Medicineen_AU
local.contributor.affiliationMcBryde, Emma, University of Melbourneen_AU
local.contributor.authoruidViney, Kerri, u4903353en_AU
local.description.embargo2037-12-31
local.description.notesImported from ARIESen_AU
local.identifier.absfor111706 - Epidemiologyen_AU
local.identifier.absfor111505 - Pharmacogenomicsen_AU
local.identifier.absfor111502 - Clinical Pharmacology and Therapeuticsen_AU
local.identifier.absseo920204 - Evaluation of Health Outcomesen_AU
local.identifier.absseo920109 - Infectious Diseasesen_AU
local.identifier.absseo920207 - Health Policy Economic Outcomesen_AU
local.identifier.ariespublicationu1067127xPUB22en_AU
local.identifier.citationvolume74en_AU
local.identifier.doi10.1093/jac/dky403en_AU
local.identifier.scopusID2-s2.0-85059264468
local.publisher.urlhttp://www.oxfordjournals.org/en_AU
local.type.statusPublished Versionen_AU

Downloads

Original bundle

Now showing 1 - 1 of 1
Thumbnail Image
Name:
01_Doan_Cost-effectiveness_of_3%E2%80%89months_2019.pdf
Size:
492.15 KB
Format:
Adobe Portable Document Format
Download

Collections

ANU Research Publications

DSpace software copyright © 2002-2026 LYRASIS